Bloch surface wave enhanced biosensor for the direct detection of angiopoietin-2 tumor biomarker in human plasma by Rizzo, Riccardo et al.
Bloch surface wave enhanced biosensor for 
the direct detection of Angiopoietin-2 tumor 
biomarker in human plasma 
RICCARDO RIZZO,1 MARIA ALVARO,2 NORBERT DANZ,3 LUCIA NAPIONE,2,4 
EMILIANO DESCROVI,1 STEFAN SCHMIEDER,5 ALBERTO SINIBALDI,6 
SUBINOY RANA,7 RONA CHANDRAWATI,7,8 PETER MUNZERT,3 THOMAS 
SCHUBERT,9 EMMANUEL MAILLART,10 ALEKSEI ANOPCHENKO,6,11 PAOLA 
RIVOLO,1 ALESSANDRO MASCIOLETTI,12 ERIK FÖRSTER,3,13 FRANK 
SONNTAG,5 MOLLY M. STEVENS,7 FEDERICO BUSSOLINO,2,14 AND 
FRANCESCO MICHELOTTI6,15 
1Department of Applied Science and Technology, Politecnico di Torino, C.so Duca degli Abruzzi 24, 
10129 Torino, Italy 
2Laboratory of Vascular Oncology, Candiolo Cancer Institute – IRCCS, Candiolo, Italy, Department of 
Oncology, University of Torino, Candiolo, Italy 
3Fraunhofer Institute for Applied Optics and Precision Engineering IOF, Albert-Einstein-Str. 7, Jena 
07745, Germany 
4Present Address: Department of Applied Science and Technology, Politecnico di Torino, C.so Duca 
degli Abruzzi 24, 10129 Torino, Italy 
5Fraunhofer Institute for Material and Beam Technology IWS Dresden, Dresden 01277, Germany 
6Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 
16, 00161 Rome, Italy 
7Department of Materials, Imperial College London, London SW7 2AZ, UK 
8Present Address: School of Chemical and Biomolecular Engineering, The University of Sydney, 
Sydney, NSW 2006, Australia 
9KDS Raderberger GmbH, Großröhrsdorf 01900, Germany 
10HORIBA Scientific, Av. de la Vauve CS 45002 - 91120 Palaiseau, France 
11Present Address: Department of Physics, Baylor University, One Bear Place #97316, 76798-7316, 
Waco, Texas, USA 
12LABOR Srl, Via G. Peroni, 00131 Rome, Italy 
13Present Address: University of Applied Sciences, Department SciTec, Jena, 07745, Germany 
14federico.bussolino@unito.it 
15francesco.michelotti@uniroma1.it 
Abstract: Quantitative detection of angiogenic biomarkers provides a powerful tool to 
diagnose cancers in early stages and to follow its progression during therapy. Conventional 
tests require trained personnel, dedicated laboratory equipment and are generally time-
consuming. Herein, we propose our developed biosensing platform as a useful tool for a rapid 
determination of Angiopoietin-2 biomarker directly from patient plasma within 30 minutes, 
without any sample preparation or dilution. Bloch surface waves supported by one 
dimensional photonic crystal are exploited to enhance and redirect the fluorescence arising 
from a sandwich immunoassay that involves Angiopoietin-2. The sensing units consist of 
disposable and low-cost plastic biochips coated with the photonic crystal. The biosensing 
platform is demonstrated to detect Angiopoietin-2 in plasma samples at the clinically relevant 
concentration of 6 ng/mL, with an estimated limit of detection of approximately 1 ng/mL. 
This is the first Bloch surface wave based assay capable of detecting relevant concentrations 
of an angiogenic factor in plasma samples. The results obtained by the developed biosensing 
platform are in close agreement with enzyme-linked immunosorbent assays, demonstrating a 
good accuracy, and their repeatability showed acceptable relative variations. 
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1. Introduction 
Tumor angiogenesis has been one of the most intensively studied areas of cancer research in 
recent years. Angiogenesis – the formation of new blood vessels from pre-existing ones – has 
an essential role in development, as well as in tissue repair and remodeling. In adults, 
angiogenesis can also occur in a number of pathological conditions including neoplastic 
disease [1]. Indeed, after reaching a diffusion-limited size, many tumors rely on an angiogenic 
switch, rendering tumor angiogenesis one of the hallmarks of cancer [2,3]. Released 
angiogenic factors establish a dynamic tumor microenvironment where intricate intracellular 
paths lead to the phenotypic changes required to sustain tumor growth. 
The angiogenic factor Angiopoietin-2 (Ang2) has been widely investigated due to its 
function in tumor vasculature and in other pathological conditions associated with endothelial 
dysfunction [4]. Particularly, in angiogenic tissues such as tumors, endothelial cells secrete 
high levels of Ang2 that promotes angiogenesis in addition to other proangiogenic factors 
such as vascular endothelial growth factor (VEGF). Ang2 levels are elevated in the plasma of 
cancer patients compared to healthy subjects; furthermore higher circulating Ang2 levels may 
correlate with a more advanced stage of the disease and/or a worse prognosis in some cancer 
types [5–8]. Ang2 may also assist in the diagnosis of difficult lesions [9]. Monitoring Ang2, 
as well as other angiogenic factors, is therefore desirable for disease diagnosis and future 
development of targeted anti-angiogenesis therapy in cancer and other diseases. 
Performing an effective shift from qualitative to quantitative biology requires new 
innovative techniques, new approaches and close interdisciplinary collaboration among 
biologists, physicists, engineers, mathematicians, chemists, and computer scientists. Building 
on this concept, we developed an optical biosensing system that is able to detect Ang2 using a 
tandem approach exploiting both label-free and fluorescence detection [10]. Such a system is 
composed of a fast and reliable analytical instrument with integrated microfluidics and of 
low-cost disposable one dimensional photonic crystal (1DPC) biochips. Previous work 
demonstrated the detection of high concentration of Ang2 in buffer [10]. Alternative 
fluorescence based sensor approaches recently reached detection below 1 ng/ml concentration 
[11] that have been further decreased by combining fluorescence and magnetic labelling [12]. 
The present work targets the ng/ml concentration range while offering to analyze different 
biomarkers and references simultaneously in microliter sample volumes and in less time 
compared to ELISA assays. ELISA is considered as reference for our assay to demonstrate 
the clinical application of the biosensing platform requires by detecting biomarker at 
biologically relevant concentrations in clinical samples. 
In general, the advent of biosensors based on photonic crystals and their improvements 
allowed the realization of simple and low-cost bioassays [13]. Indeed, during the last decade 
Bloch surface waves (BSW) sustained by 1DPC have been considered as a viable alternative 
to surface plasmon polaritons in both label-free [14–20] and fluorescence [21–23] optical 
biosensors. The most interesting feature of BSW relies on the enhanced and confined 
electromagnetic field in close proximity of the interface, leading to an increase of the label-
free resolution and of the fluorescence excitation rate of fluorophores located at the 1DPC 
surface. 
Here, we present the detection of both Ang2 spiked in buffer and endogenous Ang2 
biomarker directly from human blood plasma, with the sensing platform operating in the 
fluorescence mode only. While several BSW based biosensors [19,22,24–27] were reported 
for the detection of different analytes, their accuracy was never tested with real clinical 
samples. Blood plasma, together with serum, is one of the main sources of clinical analytes 
[28]. Although it may contain many disease biomarkers, it is one of the most complex 
analytical matrices, in which the analytes are mixed with a large number of other molecules 
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[29]. This represents a serious obstacle for the development of clinical biosensors handling 
human plasma samples. 
To the best of our knowledge this is the first BSW biosensor assay for the detection of an 
angiogenic factor (Ang2) whose accuracy has been assessed with patients’ plasma samples at 
clinically relevant concentrations. The results reported here, which are still limited to a small 
number of samples and are being extended in our present studies, can lead to a biosensing 
system, which allows the detection of Ang2 biomarker comparable with analytical quality 
laboratory methods such as enzyme-linked immunosorbent assay (ELISA). In addition, our 
method excludes any sample pretreatment, features short experimental time and is relatively 
simple to use [30]. 
2. BSW biochips 
1DPC are photonic bandgap dielectric structures [31] characterized by a spatial periodicity of 
the real dielectric constant along one direction. Depending on the dielectric contrast and 
geometry, such structures can localize the electromagnetic field in a confined region and 
enhance linear and nonlinear optical effects [32,33]. The biochips used in the present work 
were fabricated by depositing purposely designed 1DPC directly on molded plastic substrates. 
In Fig. 1(a), we show a photograph of a biochip [27] together with its microfluidic cover. The 
substrate includes an integrated coupling prism operating in the Kretschmann-Raether 
configuration under total internal reflection (TIR) conditions. Such approach leads to a 
disposable and low-cost sensor unit, which is advantageous to the practical applications. 
The substrates were fabricated by injection moulding and made out of the thermoplastic 
COC polymer (Topas 6013, Topas Advanced Polymers), with refractive index is nSUB = 1.530 
at λ = 670 nm. This is a clear amorphous non-polar polymer with low water adsorption, good 
chemical resistance, high purity and a non-reactive surface. The last point is essential for the 
desired biomedical application. As shown in Fig. 1(a), the substrate is equipped with a two-
components injection moulded flow cell. During the fabrication, in a first step, the hard cover 
is moulded and, in a second step, injection of an elastomer creates a contact layer, with one 
micro channel that runs along the sensing surface, and forms o-rings at the top of the cell. 
Such elastomer ensures proper sealing of the fluidic contacts when the complete biochip is 
inserted in the read-out system. The fluidic channel is 800 µm wide, 100 µm high, and 27 mm 
long, and contains approximately 2.2 µl volume. 
The 1DPCs were fabricated by depositing alternating low and high refractive index layers 
with optimized thicknesses. Either SiO2 (silica) or Ta2O5 (tantala) and TiO2 (titania) were 
used as low and high index materials, respectively. The complex refractive indices of these 
materials were determined by ellipsometry, making use of test multilayers sustaining BSW 
[34] at the wavelength λ = 670 nm: nSiO2 = 1.474 + i5E-6, nTa2O5 = 2.160 + i5E-5, nTiO2 = 2.28 
+ i1.8E-3. 
The design of the 1DPC used in the present work is presented in Fig. 1(b). The first silica 
layer of 275 nm was deposited to promote the adhesion of the stacks to the plastic substrate. 
The 1DPC has a periodic part made of two tantala/silica (dTa2O5 = 120 nm, dSiO2 = 275 nm) 
bilayers with the top thin bilayer made of titania/silica (dTiO2 = dSiO2 = 20 nm). 
The direct deposition of the 1DPC on the plastic substrates was carried out by means of an 
APS904 coating system (Leybold Optics) under high vacuum conditions [35]. The technique 
allows the deposition of dense coatings without substrate heating. The film densification was 
performed by the APS plasma ion source, which emits high energetic Ar-ions during the 
evaporation process in order to densify the growing film. By varying the ion energy the film 
densification can easily be adjusted, for example to balance intrinsic film stress. Ion energies 
of approximately 100 eV were applied for SiO2 with a deposition rate 0.5 nm/s and for Ta2O5 
with 0.4 nm/s. For the thin TiO2 layer 120 eV and 0.25 nm/s were used. The deposition 
chamber was adapted to coat 90 substrates in one run with high thickness uniformity [36]. 
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The BSW biochips were designed to operate in two detection modes. In the label-free 
mode, similar to surface plasmon resonance (SPR) [37], the resonant dip appearing in the TIR 
angular spectrum as a signature of the excitation of a BSW is tracked as a function of time to 
measure the change of the refractive index at the biochip’s surface due to binding of Ang2 
biomarkers. In the fluorescence based approach, the BSW field enhancement at the biochip 
surface is used to amplify the fluorescence of the labelled antibodies in a sandwich Ang2 
immunoassay [38]. In Fig. 1(b)-1(d), we summarize the results of numerical simulations 
carried out for the proposed BSW biochips, to identify the advantages arising from their use 
in both the detection modes. Figure 1(c) shows the theoretical reflectance in the 
Kretschmann-Raether TIR configuration in water environment, for both TE and TM 
polarizations. The simulations were performed using the transfer matrix method, for the two 
illumination wavelengths used in the label-free (λ1 = 670 nm, red curves) and fluorescence (λ2 
= 635 nm, blue curves) mode. In the TE case (solid), a sharp resonant dip is observed, 
corresponding to the excitation of a BSW. Figure 1(b) depicts the transverse |E|2 field 
distribution (solid) at resonance for the TE polarized BSW, compared to the bare 
substrate/water interface case (dashed, plotted only in the external medium). The strong field 
intensity enhancement and the evanescent tail in the external medium make BSW extremely 
sensitive to the perturbations of the refractive index at the 1DPC/water interface. In previous 
works, we demonstrated that the reduced linewidth (Δθ∼0.06 deg) allows a better label-free 
resolution compared to the SPR (Δθ ∼1.5 deg) [39]. Figure 1(c) shows the presence of a TM 
polarized BSW (dashed line) with much shallower resonance owing to a weaker field 
localization at the 1DPC surface, where most of the 1DPC losses occurs (TiO2 layer). 
 
Fig. 1. (a) Picture of the plastic biochip with integrated micro-optics and polymeric 
microfluidic cover, the deposited PC appears as a greenish square. (b) Normalized |E|2 field 
distribution in log scale associated to a resonantly excited TE BSW (solid) compared to the 
substrate/water interface (dashed). The curves are calculated at λ1 = 670 nm (red) and λ2 = 635 
nm (blue). The 1DPC structure is shown in the background of the figure. (c) Angular 
reflectance spectra for the TE (solid) and TM (dashed) polarization, calculated at λ1 (red) and 
λ2 (blue). (d) Angular emission patterns in log scale integrated over the DyLight 650 spectrum 
and over the two TE and TM polarizations. The curves are for molecules isotropically oriented 
and located at the interface between: (dot) substrate/external medium, (solid) 1DPC/external 
medium, (dashed) 1DPC/external medium and taking into account the effect of the intensity 
enhancement on the excitation rate. 
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Fluorescence operation takes advantage of the electric field enhancement to excite 
labelled biomolecules bound at the 1DPC surface by a second TE polarized laser beam at λ2 = 
635 nm and to force their emission into the substrate in a narrow angular range. With 
reference to Fig. 1(b)-1(c), due to the BSW dispersion, the resonant dip at λ2 is shifted to 
larger θ, whereas the field distribution is much similar to that calculated at λ1. In Fig. 1(d) we 
show the angular emission pattern IFL in the substrate, for DyLight 650 dye molecules [40] 
placed at the 1DPC/water interface. The patterns were calculated by using dyadic Green’s 
functions to describe the effects classically [41], assuming isotropically oriented dye 
molecules and integrating over the whole emission spectrum of the dye. The pattern (solid 
line) is compared to that obtained for dyes placed at a single substrate/water interface (dotted 
line), putting into evidence the enhanced emission into a narrow angular range. The pattern 
can be re-scaled (dashed line) by taking into account the TE excitation intensity enhancement, 
due to the BSW resonant excitation at λ2. The enhancement factor (∼65) was calculated as the 
ratio of the TE field intensities at the 1DPC/water and substrate/water interfaces, respectively 
at the BSW resonance and at the TIR edge. It can be observed that the combination of 
fluorescence excitation enhancement and angular redistribution results in a strong increase of 
fluorescence in a restricted angular range (62-70 deg), characterized by two bands due to 
either TE or TM components [42]. 
3. Surface chemistry, antibody immobilization and assay parameters 
3.1 Reagents 
Sulfuric acid (95-98%), hydrogen peroxide (30% in H2O), (3-aminopropyl)triethoxysilane 
(APTES, 99%), ethanol (99.8%), glutaraldehyde solution (grade I, 50% in H2O), sodium 
bicarbonate (99.7%), sodium cyanoborohydride (95%), hydrogen chloride (2 M), glycine 
(98.5%), bovine serum albumin (BSA, 98%), fetal bovine serum (FBS) and Dulbecco’s 
Phosphate Buffered Saline 1X (D-PBS) were purchased from Sigma-Aldrich and used as 
received. Dulbecco’s modified Eagle medium (DMEM) was purchased from Lonza. 
NeutrAvidin Protein DyLight 650 (1 mg/mL) (NeutrAvidin 650) was purchased from Thermo 
Fisher Scientific. Anti-human Angiopoietin-2 (Anti-Ang2) capture antibody, biotinylated 
anti-human Angiopoietin-2 detection antibody (Anti-Ang2*), anti-human VEGF capture 
antibody (Anti-VEGF), recombinant human Angiopoietin-2 protein (97%), and human 
Angiopoietin-2 Quantikine ELISA Kit were purchased from R&D System. Water was 
purified by a Millipore device. 
3.2 Immobilization procedures 
The immobilization procedure started with surface chemical functionalization of the 1DPC 
biochips carried out by APTES chemistry and taking advantage of the last 20 nm thick SiO2 
layer [43]. Before APTES, the biochips’ surface was cleaned with piranha (H2SO4:H2O2 = 
3:1) for 10 minutes, washed thoroughly using de-ionized (DI) water and ethanol and dried 
with N2. The clean biochips were dipped in a 2% (v/v) solution of APTES in a mixture of 
ethanol/water (95:5 v/v) for 1 hour and then dipped in pure ethanol and sonicated three times. 
After rinsing with pure ethanol and drying with N2 we baked the biochips on a hot plate at 
110 °C for 1 hour. The efficiency of the functionalization was checked by contact angle 
measurements and immunodetection assays. 
Glutaraldehyde (GAH) was used as a homobifunctional agent to couple the APTES-
functionalized surface with the antibodies to be immobilized on the surface. The prepared 
biochips were dipped in a solution of 1% (v/v) GAH in 100 mM sodium bicarbonate buffer 
(pH 8.5) in the presence of 0.1 mM NaCNBH3 for 1 hour. A last sonication was performed in 
DI water followed by a thorough wash with DI water. 
Incubation of specific and non-specific monoclonal antibodies was carried out by means 
of a five-channel Polydimethylsiloxane (PDMS) flow cell used for wet spotting. The channels 
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are 200 µm wide, 200 µm high and are separated by a 200 µm PDMS wall. They can be filled 
and emptied with protein solutions to be immobilized by using a standard microliter pipette. 
This strategy allows to define signal (positive) and reference (negative) spots on the 
biochip surface along the illumination strip, as shown in Fig. 2. The on-chip references are 
used to subtract any signal that arises from non-specific binding events. 
Two channels were used to incubate 20 µg/mL of the anti-Ang2 capture antibody (signal 
spots, positive), two channels were filled with 20 µg/mL of the anti-VEGF antibody 
(reference spots, negative) and one was dedicated to BSA, 10 mg/mL, (reference spot, 
negative). The volume used was 20 µL for each channel. The immobilization step lasted 1 
hour. After the removal of the spotting tool, the biochips were rinsed with D-PBS and 
incubated overnight in a solution of 10 mg/mL of BSA in D-PBS at 4 °C, in order to block the 
surface. Four biochips were prepared at a time. All concentrations, volumes and times of the 
functionalization and immobilization procedures were adjusted to obtain the best sensor 
performance. 
After the immobilization procedure, each 1DPC biochip was topped with the microfluidic 
cover shown in Fig. 1(a) and mounted on the platform. Before starting any assay, 1 mL of 
glycine-HCl (20 mM, pH 2.5) was injected and recirculated for 10 minutes to remove from 
the surface any not-covalently bound BSA biomolecule, which could overlay the capture 
antibodies. 
4. Read-out system 
The optical layout of the platform was designed to operate either detecting the angular 
reflectance at λ1 or exploiting the BSW field enhancement when exciting at λ2 and detecting 
BSW coupled fluorescence, peaked around λ1, from DyLight 650 labelled antibodies in a 
sandwich Ang2 immunoassay [10]. However, the estimated limit of detection (LoD) of the 
label-free operation (about 11 ng/mL) is not sufficient for the detection of Ang2 at very low 
and clinically relevant concentrations, whereas the estimated LoD of the fluorescence mode 
(about 1 ng/mL) falls within the relevant range [27]. Therefore, in the present work we 
carried out Ang2 detection assays in the fluorescence mode only. Nevertheless, the label-free 
operation provides useful information on kinetic constants and affinity, for assays carried out 
at larger concentrations. It should be noted that the LoD strongly depends on surface 
chemistry and capture/detection antibody affinity. Therefore, depending on the types of 
cancer biomarkers and immunoassays, the same label-free scheme can provide a lower, and 
clinically relevant, LoD [26]. 
Given that we focus on the fluorescence mode, here the optical layout for label-free mode 
is only briefly described. Label-free operation is achieved through a TE polarized laser beam 
at λ1 that is focused by a cylindrical lens into the polymer chip, thus illuminating a line at the 
sensor surface. The reflected light is angularly imaged onto the CCD image sensor and the 
BSW resonant dip is tracked as a function of time. 
In Fig. 2, we sketch the optical system used in the fluorescence mode of operation. The 
collimated beam of a laser diode at λ2 is focused by means of the cylindrical excitation lens 
(EL) into the chip, thus generating an excited line (sensing area indicated in blue in Fig. 2). 
The excitation beam can be laterally scanned to change the illumination angle and to ensure 
matching to the BSW resonance angle at λ2 (compare Fig. 1(c)). Such a scanning of the 
illumination angle allows for compensating refractive index induced shifts of the resonance 
position during an assay. A filter set including excitation and emission filters (not shown) and 
a dichroic splitter (SP) are used to adjust the correct position of the illumination line and to 
separate excitation and emission spectral ranges. 
The detection of fluorescence generated on top of the chip surface is achieved by two 
cylindrical optical systems. First, a system of cylindrical lenses (indicated by L1 and L2 in 
Fig. 2) images a 5 mm long part of the illuminated line onto the short axis of a CCD sensor. 
This approach reaches a lateral resolution below 100 µm to allow for simultaneously 
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analyzing up to 20 spots. In the present work, five different measurement regions have been 
used only. Second, the angular spectrum of emission is imaged by means of a cylindrical 
Fourier lens (FL) onto the long axis of the CCD sensor. As fluorescence is coupled to BSW, 
each wavelength component of the spectrum is emitted at a different angle due to the 
dispersion of the BSW [10,42,44]. The observed angular range in the fluorescence mode is 
increased to approximately 8 deg, compared to 2.9 deg in the label-free mode, by introducing 
a cylindrical angular zoom lens (AZ). Therefore, almost all the fluorescence energy emitted 
into the BSW dispersion by the DyLight 650 labels is detected. 
 
Fig. 2. Sketch of the fluorescence mode optical system without plotting laser diode 
collimation. Fluorescence excitation (blue) and emission (red) are shown with an arrangement 
of five spots along the illuminated line. The positive (Anti-Ang2) and negative regions (Anti-
VEGF and BSA) were obtained with the five-channel functionalization flow cell on top of the 
biochip. The two axes of the CCD detector represent the position along the illuminated line on 
the chip as well as the angular spectrum of emission. 
The CCD sensor mounted in the detection system is an APOGEE Ascent with Sony 
ICX814, with a 3388x2712 pixel matrix. The lasers are from Hitachi: HL6714 (λ1) and 
HL63133DG (λ2). The filter set is from Chroma: excitation filter ZET 635/20, bandpass 
emission filter ET 685/70; dichroic beam 45 deg splitter (SP) ZT 640 rdc. Lenses are ar-
coated in the visible range. Lateral scanning of the fluorescence excitation laser is provided 
by a motorized stage from Thorlabs. 
In case dyes emitting in a different spectral range are used ((e.g., Atto532, 
AlexaFluor532)), the operation principle of the platform does not change. One could adapt 
the 1DPC design and the operation wavelength of the label-free operation mode. 
5. Results 
5.1 Biological samples 
Plasma samples were collected at the Candiolo Cancer Institute – IRCCS (Italy), in 
accordance with the protocol approved by the Institute’s Ethical Commission and the Ethical 
Committee Piedmont Region, Torino (Italy). As inclusion criteria, the protocol considered 
patients with metastatic colon cancer, in treatment with bevacizumab [45] in combination 
with other chemotherapy agents, and having signed the informed consent. Blood sampling 
was done before, during, and after the therapy. 
Plasma was prepared by centrifugation of the whole blood contained in the test tube with 
EDTA as anticoagulant; after centrifugation the corpuscular fraction was discarded and the 
supernatant was collected, aliquoted and stored at −80°C. 
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5.2 Immunoassay format 
When a sample solution flows over a bio-conjugated biochip (Fig. 3(a)), Ang2 target 
molecules can be captured at the surface (Fig. 3(b)) and results in a shift of the BSW 
resonance that can be detected in the label-free mode. For fluorescence operation, we injected 
in the biochip a biotinylated anti-Ang2* detection antibody solution, followed by 
fluorescence background measurement and labelling of the antibody by injecting an 
appropriate fluorophore (NeutrAvidin Protein DyLight 650, Fig. 3(c)). The biochip is finally 
washed by flowing D-PBS and fluorescence detection is performed in D-PBS upon excitation 
at λ2 (Fig. 3(d)). The overall duration of the assay is 30 minutes. 
 
Fig. 3. Schematic of the sandwich assay for the detection of Ang2 biomarker using the 
fluorescence mode. 
In all assays the concentration of both anti-Ang2* and NeutrAvidin 650 solutions was 1 
µg/mL in D-PBS. The volume of all solutions used, from that containing the target biomarker 
to that used for dye labelling, was 400 µL. All solutions were recirculated for 10 minutes by 
forth and back pumping. The flow rate for all the injection and recirculation steps was 30 
µL/min. Between each assay step, the microfluidic channel was rinsed with abundant D-PBS 
increasing the flow rate to 50 µL/min. 
 
Fig. 4. (a) Fluorescence emission recorded by the CCD camera at the end of an assay, where 
Ang2 was detected; (b) Angular emission profiles along the dashed lines. 
Figure 4(a) displays the image provided by the CCD sensor at the end of an assay, in 
which a solution containing Ang2 was injected in the biochip. Fluorescence intensity is 
collected over the 8 deg angular range. A clear fluorescence signal emerges from spots that 
are bio-conjugated with anti-Ang2, while signal collected from the reference spots is 
negligible. Two clearly visible peaks are due to the coupling of the fluorescence emission to 
either the TE or TM BSW mode, in agreement with the simulations shown in Fig. 1 [10,25]. 
The shape of the emission profile is related to the DyLight 650 emission spectrum via the 
dispersion of the TE and TM polarized BSW; for a given 1DPC design, it is therefore a 
characteristic signature of such a dye [27]. 
For each spot, the angularly dispersed fluorescence emissions in 50 adjacent CCD camera 
rows were acquired. Next, we subtracted the background fluorescence, followed by 
integrating the angular intensity distribution in each CCD row (Fig. 4) along the angle. 
Hence, the integral values are averaged over the 50 rows and assigned an intensity and 
standard deviation. 
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5.3 Calibration assays 
A calibration is needed to use the BSW platform for quantifying Ang2 levels in patients’ 
plasma. For this purpose, duplicate standards of Ang2 were prepared in D-PBS by serial 
dilution of a stock solution of 0.1 mg/mL of Ang2 in D-PBS. Calibration data points were 
obtained for the following concentrations: 2.5, 5, 10, 20 and 50 ng/mL. The concentration 
was varied in such a range given that the Ang2 levels in cancer patients are generally higher 
than 1 ng/mL [6,46,47]. Pure D-PBS was used as a negative control. All calibration assays 
were performed with freshly bio-conjugated BSW biochips and in duplicate. In view of a 
clinical application of the platform, calibration with standards diluted in a matrix with 
complexity similar to that of human plasma will be needed. 
 
Fig. 5. Fluorescence intensities recorded for the standard Ang2 solutions at different 
concentrations in D-PBS. (a) Fluorescence intensities recorded by the CCD at the end of the 
assay. (b) Integrated and averaged intensities for each group of spots on the BSW biochip; the 
error bars represent the standard deviation associated with the integrated and averaged values. 
Figure 5(a) shows the fluorescence intensities for each concentration recorded by the 
CCD. All measurements were carried out with the same CCD exposure time. When only D-
PBS is injected during an assay carried out with exactly the same steps of the protocol (just 
without the target molecule), the platform detects a very low uniform signal from the whole 
surface. It also appears that any detection antibody, together with any NeutrAvidin 650 label, 
are non-specifically absorbed onto the sensor surface resulting in a non-specific fluorescence 
signal even after the background correction. However, the signal measured in the anti-Ang2 
regions can be distinguished with a good contrast. 
In Fig. 5(b), we plot the integrated and averaged fluorescence signal measured in 
analogues spots, i.e. the sensor area bio-conjugated with the same molecules. The bar plot 
shows increasing signal in response to the increasing Ang2 concentrations. Standard 
deviations of the mean values are calculated as the sum of the variances associated with the 
signal emitted from each region. Such standard deviations spread with increasing Ang2 
concentration but relative values are constant. The overall response of the BSW platform is 
determined by the difference between the averaged intensities recorded in the Anti-Ang2 
spots and in the reference spots. Figure 5(b) shows that the lowest Ang2 concentration of 2.5 
ng/mL can be clearly detected. 
The average overall responses of the two duplicate measurements carried out for each 
concentration, and their respective standard deviations calculated as the square root of the 
sum of the variances, can be plotted as a function of the Ang2 concentration, as shown in Fig. 
6, and the resulting calibration curve can be used in assays with unknown Ang2 content. 
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 Fig. 6. Calibration curve of Ang2 in D-PBS. Each point represents the difference between the 
averaged intensities recorded in the Anti-Ang2 spots and in the reference spots averaged on 
two replicate measurements. The coefficient of variation (CV) of the data points is 18%, 6.5%, 
7.3%, 4.5%, 4.4%, from the lowest to the highest concentration respectively. 
5.4 Detection of Ang2 in human plasma samples 
Applicability of the present sensor in clinics was investigated by quantifying Ang2 
concentrations in human plasma samples from metastatic colorectal cancer patients. Each 
plasma sample was simultaneously validated by performing ELISA to quantify the Ang2 
concentration in one aliquot. The ELISA tests on plasma samples collected from cancer 
patients before the therapy, showed an Ang2 median, minimum and maximum concentration 
of 4.5 ng/ml, 1.4 ng/ml, and 8.2 ng/ml, respectively. 
Table 1. Ang2 concentrations in plasma samples from metastatic colorectal cancer 
patients as estimated by both the ELISA and the BSW platform. For the BSW system, 
each calculated value is the mean of two duplicate experiments. 
  
Detected Ang2 concentration [ng/mL] 
Plasma Sample ELISA 
 
BSW platform (σ) 
S1 6.7 6.2 (0.4) 
S2 5.7 5.8 (0.4) 
S3 5.8 5.3 (0.2) 
Among all the collected plasma, three samples (here reported as plasma S1, S2 and S3) 
were assayed with the BSW platform, dropping those with the largest and smallest Ang-2 
concentration, as determined by the ELISA test. S1 and S2 were collected from the same 
patient before and during the therapy, respectively; while S3 was from a second patient after 
the therapy. The calibration curve shown in Fig. 6 was used to evaluate the Ang2 
concentration from the averaged fluorescence intensities. For each plasma sample the assay 
was repeated twice, in different days and using fresh BSW biochips. The results are reported 
in Table 1 and compared to the values previously retrieved from ELISA assays carried out 
with the same plasma samples. The ELISA assays were carried out by the Quantikine Kit 
from R&D and according to the manufacturer's instructions; for such assays the plasma 
samples were 1:5 and 1:10 diluted. 
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6. Discussion 
The assays performed with the human plasma samples show that Ang2 can be detected by the 
BSW platform at clinically relevant concentrations in human plasma. A good agreement with 
the ELISA control assays is found, with a deviation of less than 10%, as shown in Table 1. 
Such a result demonstrates the good accuracy of the BSW platform to the standard laboratory 
tests such as ELISA. 
According to both ELISA and BSW determination, the Ang2 concentration was around 5-
6 ng/mL in all three human plasma samples. 
Data reported in Fig. 6 can be fitted to a sub-linear calibration function, which can be then 
extrapolated to low concentration to evaluate the limit of detection (LoD) of the immunoassay 
implemented on the BSW platform in fluorescence mode. As a fitting function, we used a 










where F is the measured fluorescence intensity, c is the Ang2 concentration, A1 and A2 are the 
background and maximum fluorescence intensities, respectively. Such a functional 
dependency accounts for the linear behavior at low concentration and for the sub-linear 
dependency at large concentration, which can be either due to the Langmuir model or also to 
the fact that the fluorescence signal produced by the 50 ng/mL solution almost saturated the 
CCD detector. The slope in the linear region in the limit of low concentration is S = (430 ± 
77) counts / (ng/mL) and provides the sensitivity of the BSW platform in the fluorescence 
mode. 
According to other methods commonly reported in literature [49,50], one can estimate the 
LoD = 2σ/S = (1.0 ± 0.2) ng/mL, where the standard deviation of the smallest concentration 
(σ = 220 counts) is used. The 2σ limit is consistent with the procedures used to evaluate the 
LoD of the ELISA method. The value of the estimated LoD is in our opinion reliable, since 
(1) the extrapolation interval is indeed small (from 2.5 to 1 ng/mL on a 50 ng/mL span), (2) 
the 2.5 ng/mL was clearly detected and (3) the platform’s results coincide with the reference 
ELISA experiments. Together with the minimum concentration detected in the calibration 
assays (2.5 ng/mL), the estimated LoD is compatible with the concentration ranges of Ang2 
in plasma from patients with colorectal cancer [6]. 
Table 2. Assay percent variations in plasma samples measurements and in the calibration 
procedure. 
  Human plasma samples  Mean 





 6.68  7.23  3.18  5.70 
  Calibration standards [ng/mL]  Mean 




 5.90 5.53 7.62 5.14 5.34  5.78 
The BSW platform repeatability was assessed by evaluating the results obtained in the 
different assays, carried out with the same protocol for the same plasma sample. The relative 
variation for plasma sample measurements are reported in percent in Table 2. The table also 
presents the variability of the calibration procedure. As already mentioned, duplicate 
standards were prepared for each concentration (2.5, 5, 10, 20, 50 ng/mL) and were assayed 
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with separate BSW biochips. Mean values of the relative variation are below 6% for both 
plasma measurements and standards. Moreover, all the individual values are below 10%, 
which is acceptable for an analytical method. 
7. Conclusions 
We demonstrated that the BSW biosensing platform described in the present work is suitable 
for the detection of relevant clinical levels of the angiogenic factor Ang2 in patient plasma 
samples. To the best of our knowledge this is the first BSW based biosensor assay for the 
determination of Ang2 in plasma samples at clinically relevant concentrations. The system 
takes advantage of BSW sustained by purposely designed 1DPC to excite and enhance a 
fluorescent immunoassay involving Ang2. The minimum Ang2 concentration in D-PBS that 
the platform detected is 2.5 ng/mL. The limit of detection in the fluorescence mode was 
evaluated to be (1.0 ± 0.2) ng/mL. Both values are compatible with clinically relevant Ang2 
concentrations. The system is capable of assessing Ang2 concentration in plasma samples 
using small sample volumes (300 µL) with a short experimental time (30 minutes) and 
without sample pretreatment or dilution. The robustness was demonstrated by the good 
repeatability proven by low relative variation. The Ang2 plasma concentrations determined 
with the BSW system were validated by ELISA measurements and a good agreement 
between both the results was found, demonstrating the accuracy of our system. The limited 
number of plasma samples used in the present work does not yet permit to compare the 
developed BSW platform with a gold standard assay, since power regression analysis will 
have to be performed with a larger number of patient samples over a more extended Ang-2 
concentration range. For this reason, at the present stage, we cannot correlate the 
concentration levels found with the platform to the clinical history of the patients. However, 
the outcome of the present work confirms that the BSW biosensing platform is a valuable tool 
for fast diagnosis of angiogenic factors and paves the way for the development of multiplexed 
BSW biosensors for the detection and monitoring of multiple clinical biomarkers. 
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